

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Yestar Healthcare Holdings Company Limited**

**巨星醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2393)**

### **TERMINATION OF THE POSSIBLE SUBSCRIPTION AND NO WHITEWASH WAIVER WILL BE REQUIRED**

References are made to the announcements of the Company dated 8 April 2022 (the “**Possible Subscription Announcement**”), 6 May 2022, 6 June 2022, 28 June 2022, 28 July 2022 and 15 August 2022 in relation to, among other things, the Possible Subscription (together, the “**Announcements**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those ascribed to them in the Announcements.

#### **TERMINATION OF THE POSSIBLE SUBSCRIPTION**

As disclosed in the Possible Subscription Announcement, the Memorandum of Understanding may be terminated by mutual written agreement.

The parties to the Memorandum of Understanding have not reached a consensus on the key terms in relation to the Possible Subscription and thus mutually agreed to terminate the Memorandum of Understanding (including the Supplemental Memorandum of Understanding) after negotiation. On 23 August 2022, the Company and the Potential Investor entered into a termination agreement to terminate the Memorandum of Understanding (including the Supplemental Memorandum of Understanding) and the Possible Subscription (the “**Termination**”). Upon the Termination, neither party to the Memorandum of Understanding shall have any obligations towards the other party in connection with breach of the Memorandum of Understanding (including the Supplemental Memorandum of Understanding). Each of the parties shall bear its own costs incurred prior to the Termination (including the costs in relation to the engagement of agents and advisers), and neither party is required to pay any costs or other compensation for the other party.

As the Company will not proceed the Possible Subscription, the Company will cease to publish further monthly announcements in respect of the progress of the Possible Subscription pursuant to a possible application for whitewash waiver under the Takeovers Code.

The Board considers that the Termination should have no material adverse impact on the financial position and operations of the Group.

**Shareholders and potential investors are advised to exercise caution when dealing in the Shares and if they are in any doubt about their position, they should consult their professional adviser(s).**

By order of the Board  
**Yestar Healthcare Holdings Company Limited**  
**Hartono James**  
*Chairman and Non-executive Director*

24 August 2022

*As at the date of this announcement, the executive Directors are Ms. Wang Hong, Ms. Liao Changxiang and Mr. Liang Junxiong; the non-executive Director is Mr. Hartono James; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.*